Several applications for generic semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, are currently under review by Health Canada, as the patent for Ozempic is set to expire due to Novo Nordisk’s failure to pay maintenance fees. This opens the market for cheaper alternatives, with a U.S. telehealth service planning to offer generic versions at a significant discount, potentially impacting weight-loss drug usage and social dynamics, particularly in dating.
Explain It To Me Like I’m 5: Several applications for generic versions of semaglutide, the active ingredient in Novo Nordisk’s popular drugs Ozempic and Wegovy, are currently under review by Health Canada following the expiration of the drug’s patent in Canada.
Want More Context? 🔎
